A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Inclusion Criteria: * Relapsed or progressive advanced solid tumor malignancies * Measurable or non-measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Life expectancy greater than 3 months * Resolution of all acute toxic effects of prior chemotherapy, and other cancer treatments * Adequate bone morrow and kidney function * No signs of decompensated liver cirrhosis or ascites requiring therapeutic paracentesis * Agree to use adequate contraception Exclusion Criteria: * Previous chemotherapy, immunotherapy, chemo-embolization, targeted therapy or investigational agent for malignancy within 4 weeks prior to day 1 * Cytochrome P450 CYP3A4 inducers and inhibitors within 4 weeks prior to day 1 * Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing grapefruit or Seville oranges within 14 days prior to day 1 * UGT1A1 genotype of TA 7 in both alleles (homozygous UGT1A1\*28) or TA 8 in either one or both alleles (hetero- or homozygous for UGT1A1\*37) * Major surgery within 4 weeks prior to day 1 * Undergone a liver or other organ transplant * Concurrent treatment with other anti-cancer therapy * Untreated central nervous system metastases * Ongoing or active infection * Chronic or acute GI disorders resulting in diarrhea * Pregnancy or lactation